MRNA vs SNPS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 30, 2026

MRNA

52.3
AI Score
VS
MRNA Wins

SNPS

46.4
AI Score

Investment Advisor Scores

MRNA

52score
Recommendation
HOLD

SNPS

46score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA SNPS Winner
Revenue 389.00M 4.68B SNPS
Net Income -1.34B 82.06M SNPS
Net Margin -345.2% 1.8% SNPS
Operating Income -1.39B 323.47M SNPS
ROE -18.1% 0.3% SNPS
ROA -11.7% 0.2% SNPS
Total Assets 11.49B 46.89B SNPS
Cash 1.91B 2.41B SNPS
Debt/Equity 0.08 0.33 MRNA
Current Ratio 2.41 1.43 MRNA
Free Cash Flow -692.00M 1.40B SNPS

Relative Price Performance (Last 90 Days)

MRNA 1M: -22.7% · 3M: +21.9% SNPS 1M: -6.2% · 3M: -17.7%

Current Technical Phase

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.2 · Price: $59.17

SNPS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 54

RSI (14): 53.6 · Price: $415.99

Fundamentals Snapshot

Metric MRNA SNPS
Market Cap
Forward P/E -11.0 24.1
Trailing P/E 92.6
Revenue (TTM)
Revenue Growth 0.0% 0.4%
Gross Margin -0.7% 0.8%
Operating Margin -5.6% 0.1%
EPS -7.88 4.33
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.